Ameriprise Financial, Inc., Columbia Management Investment Advisers, LLC, and Seligman Healthcare Spectrum (Master) Fund filed a Schedule 13G Amendment No. 1 with the SEC on November 16, 2026, disclosing beneficial ownership positions in Palisade Bio, Inc. common stock as of September 30, 2026.
Key Highlights
- Aggregate stake: Ameriprise Financial, Inc. and Columbia Management Investment Advisers, LLC each report beneficial ownership of 14,567,993 shares, representing 8.4% of Palisade Bio, Inc. common stock.
- Fund-level position: Seligman Healthcare Spectrum (Master) Fund separately reports beneficial ownership of 11,988,235 shares, representing 6.9% of the class.
- Voting structure: Both Ameriprise Financial and Columbia Management Investment Advisers hold 0 shares with sole voting or sole dispositive power; all 14,567,993 shares are reported under shared voting and shared dispositive power.
- Fund voting: Seligman Healthcare Spectrum (Master) Fund reports sole voting power over 11,988,235 shares and shared dispositive power over the same amount, with 0 shares under sole dispositive power.
- Disclaimers: According to the filing, "each of AFI and CMIA, and the subsidiaries identified on the attached Exhibit I, disclaims beneficial ownership of any shares reported on this Schedule."
- No direct ownership: The filing states that "CMIA and AFI do not directly own any shares of Common Stock of the issuer."
Ownership Structure and Relationships Among the Three Reporting Persons
According to the Schedule 13G Amendment No. 1, the three reporting persons - Ameriprise Financial, Inc. ("AFI"), Columbia Management Investment Advisers, LLC ("CMIA"), and Seligman Healthcare Spectrum (Master) Fund ("FUND") - are connected through an investment advisory and parent holding company structure. The filing states that CMIA serves as the investment adviser to the Fund and various other unregistered and registered investment companies and managed accounts, and may therefore be deemed to beneficially own the shares reported by the Fund. AFI, as the parent holding company of CMIA, may in turn be deemed to beneficially own the shares reported by CMIA.
The filing discloses that the event requiring the statement occurred on September 30, 2026. As of that date, the aggregate amount beneficially owned by AFI and CMIA is reported as 14,567,993 shares, equal to 8.4% of the class. The Fund's separately reported position of 11,988,235 shares is included within the totals reported by CMIA and AFI. The CUSIP number for Palisade Bio, Inc. common stock is listed as 696389402, and the issuer's principal executive offices are located at 4600 South Syracuse Street, Suite 900, Denver, Colorado 80237.
The filing further discloses that, to the knowledge of AFI, CMIA, and the Fund, as of September 30, 2026, only the Fund owned more than 5% of the class of securities reported. Any remaining shares reported by CMIA are described as held by various other funds or accounts managed by CMIA, none of which individually own more than 5% of outstanding shares, according to the filing. AFI is organized in Delaware, CMIA in Minnesota, and the Fund in Massachusetts.
What Was Disclosed
Three affiliated reporting persons filed a Schedule 13G amendment disclosing beneficial ownership in Palisade Bio, Inc. common stock as of September 30, 2026. Ameriprise Financial and Columbia Management Investment Advisers each reported 14,567,993 shares (8.4%), with Seligman Healthcare Spectrum (Master) Fund reporting 11,988,235 shares (6.9%) within that total.




Please wait processing your request...